Neuraxis Inc (NRXS)

$2.9

-0.12

(-3.97%)▲

Live

Performance

  • $2.80
    $3.10
    $2.90
    downward going graph

    3.45%

    Downside

    Day's Volatility :9.68%

    Upside

    6.45%

    downward going graph
  • $1.80
    $3.89
    $2.90
    downward going graph

    37.93%

    Downside

    52 Weeks Volatility :53.73%

    Upside

    25.45%

    downward going graph

Returns

PeriodNeuraxis IncIndex (Russel 2000)
3 Months
-1.95%
0.0%
6 Months
-4.88%
0.0%
1 Year
19.84%
0.0%
3 Years
-49.67%
-23.0%

Highlights

Market Capitalization
20.2M
Book Value
-$0.77
Earnings Per Share (EPS)
-2.23
Wall Street Target Price
7.5
Profit Margin
0.0%
Operating Margin TTM
-360.89%
Return On Assets TTM
-260.29%
Return On Equity TTM
0.0%
Revenue TTM
2.3M
Revenue Per Share TTM
0.4
Quarterly Revenue Growth YOY
-5.3%
Gross Profit TTM
0.0
EBITDA
-8.6M
Diluted Eps TTM
-2.23
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Neuraxis Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 158.62%

Current $2.90
Target $7.50

Company Financials

FY20Y/Y Change
Revenue
1.9M
-
Net Income
-4.1M
-
Net Profit Margin
-209.83%
-
FY21Y/Y Change
Revenue
2.7M
↑ 40.98%
Net Income
-3.1M
↓ 24.12%
Net Profit Margin
-112.93%
↑ 96.9%
FY22Y/Y Change
Revenue
2.7M
↓ 1.34%
Net Income
-4.8M
↑ 55.54%
Net Profit Margin
-178.05%
↓ 65.12%
FY23Y/Y Change
Revenue
2.5M
↓ 8.37%
Net Income
-14.6M
↑ 205.99%
Net Profit Margin
-594.57%
↓ 416.52%
Q1 FY23Q/Q Change
Revenue
805.1K
↑ 31.32%
Net Income
-2.2M
↑ 15848.12%
Net Profit Margin
-269.95%
↓ 267.73%
Q2 FY23Q/Q Change
Revenue
646.0K
↓ 19.76%
Net Income
-2.2M
↑ 2.86%
Net Profit Margin
-346.06%
↓ 76.11%
Q3 FY23Q/Q Change
Revenue
477.5K
↓ 26.09%
Net Income
-4.9M
↑ 119.37%
Net Profit Margin
-1.0K%
↓ 681.12%
Q4 FY23Q/Q Change
Revenue
531.5K
↑ 11.31%
Net Income
-5.3M
↑ 8.34%
Net Profit Margin
-999.76%
↑ 27.42%
Q1 FY24Q/Q Change
Revenue
646.6K
↑ 21.67%
Net Income
-2.1M
↓ 60.09%
Net Profit Margin
-327.95%
↑ 671.81%
Q2 FY24Q/Q Change
Revenue
611.5K
↓ 5.43%
Net Income
-2.9M
↑ 37.59%
Net Profit Margin
-477.14%
↓ 149.19%
FY20Y/Y Change
Total Assets
2.8M
-
Total Liabilities
1.1M
-
FY21Y/Y Change
Total Assets
760.5K
↓ 72.74%
Total Liabilities
1.6M
↑ 38.43%
FY22Y/Y Change
Total Assets
1.5M
↑ 94.7%
Total Liabilities
7.1M
↑ 344.74%
FY23Y/Y Change
Total Assets
509.5K
↓ 65.59%
Total Liabilities
1.9M
↓ 72.89%
Q1 FY23Q/Q Change
Total Assets
1.6M
↑ 6.6%
Total Liabilities
9.3M
↑ 32.2%
Q2 FY23Q/Q Change
Total Assets
1.5M
↓ 2.45%
Total Liabilities
11.5M
↑ 23.56%
Q3 FY23Q/Q Change
Total Assets
1.2M
↓ 19.73%
Total Liabilities
2.3M
↓ 80.06%
Q4 FY23Q/Q Change
Total Assets
509.5K
↓ 58.78%
Total Liabilities
1.9M
↓ 16.73%
Q1 FY24Q/Q Change
Total Assets
945.7K
↑ 85.62%
Total Liabilities
4.1M
↑ 115.93%
Q2 FY24Q/Q Change
Total Assets
2.6M
↑ 178.45%
Total Liabilities
7.9M
↑ 91.07%
FY20Y/Y Change
Operating Cash Flow
-4.1M
-
Investing Cash Flow
-27.7K
-
Financing Cash Flow
6.1M
-
FY21Y/Y Change
Operating Cash Flow
-2.2M
↓ 46.02%
Investing Cash Flow
-1.4K
↓ 94.99%
Financing Cash Flow
661.1K
↓ 89.08%
Q1 FY23Q/Q Change
Operating Cash Flow
-622.9K
↑ 190.65%
Investing Cash Flow
-7.6K
↑ 0.0%
Financing Cash Flow
422.3K
↓ 17.2%
Q2 FY23Q/Q Change
Operating Cash Flow
-625.2K
↑ 0.37%
Investing Cash Flow
-5.5K
↓ 28.25%
Financing Cash Flow
636.7K
↑ 50.77%

Technicals Summary

Sell

Neutral

Buy

Neuraxis Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Neuraxis Inc
Neuraxis Inc
4.14%
-4.88%
19.84%
-49.67%
-49.67%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Neuraxis Inc
Neuraxis Inc
NA
NA
NA
0.0
0.0
-2.6
NA
-0.77
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Neuraxis Inc
Neuraxis Inc
Buy
$20.2M
-49.67%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Neuraxis Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 646.63K → 611.5K (in $), with an average decrease of 5.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -2.12M → -2.91M (in $), with an average decrease of 37.6% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 76.6%

Company Information

Organization
Neuraxis Inc
Employees
19
CEO
Mr. Brian Carrico
Industry
Miscellaneous

Discover More

FAQs